Inventor · disambiguated record
Anthony Nicholas
Also filed as: NICHOLAS ANTHONY · NICHOLAS ANTHONY L
15 granted patents·15 pending applications·18 citations·filing 2016–2025
88Inventor score
Top patents by PatentIndex Score
30 records- 0192US11629349B2RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Apr 18, 2023·3 cites·14 claims
- 0292US11549112B1RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Jan 10, 2023·3 cites·14 claims
- 0386US11845937B2RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2023·Granted Dec 19, 2023·1 cites·22 claims
- 0486US11180529B2Alpha-v beta-6 integrin ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Nov 23, 2021·3 cites·18 claims
- 0586US10927373B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Feb 23, 2021·2 cites·20 claims
- 0686US9976141B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD MADISON INC·Filed 2016·Granted May 22, 2018·5 cites·32 claims
- 0781US10590416B2RNAi agents for inhibiting expression of alpha-ENaC and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Mar 17, 2020·1 cites·52 claims
- 0876US2023139166A1RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0976US2023125671A1RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1075US2025034577A1RNAi Agents for Inhibiting Expression of PNPLA3, Pharmaceutical Compositions Thereof, and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1174US11840688B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Dec 12, 2023·0 cites·20 claims
- 1271US2022090077A1RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1369US12173086B2Alpha-v beta-6 integrin ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Dec 24, 2024·0 cites·15 claims
- 1469US11214802B2RNAi agents for inhibiting expression of alpha-ENaC and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Jan 4, 2022·0 cites·42 claims
- 1569US2024392292A1RNAi Agents for Inhibiting Expression of Coronavirus (CoV) Viral Genomes, Compositions Thereof, and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1666US12054718B2RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Aug 6, 2024·0 cites·34 claims
- 1766US2025034578A1Subcutaneous Delivery of RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-productsARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1865US11912997B2RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2023·Granted Feb 27, 2024·0 cites·30 claims
- 1963US2023265437A1RNAi Agents for Inhibiting Expression of Matrix Metalloproteinase 7 (MMP7), Compositions Thereof, and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2060US12365897B2RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Jul 22, 2025·0 cites·18 claims
- 2160US2023013022A1RNAi Agents for Inhibiting Expression of Beta-ENaC, Compositions Thereof, and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2259US2025376688A1RNAi Agents for Inhibiting Expression of Proprotein Convertase Subtilisin Kexin 9 (PCSK9), Pharmaceutical Compositions Thereof, and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2358US2025333738A1Polynucleic acid molecules for inhibiting expression of angptl3, pharmaceutical compositions, and uses thereofSIRIUS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2456US12486502B2RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Dec 2, 2025·0 cites·13 claims
- 2556US2025361508A1Polynucleic acid molecules targeting agt and uses thereofSIRIUS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2651US12221610B2RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Feb 11, 2025·0 cites·20 claims
- 2750US2025250573A1Polynucleic acid molecules for inhibiting expression of fxi, pharmaceutical compositions, and uses thereofSIRIUS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2848US2025188465A1Polynucleic acid molecules targeting apoc3 and uses thereofSIRIUS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2948US2025188464A1Polynucleic acid molecules for inhibiting expression of lp(a), pharmaceutical compositions, and uses thereofSIRIUS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3041US2021093725A1Integrin targeting ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Anthony Nicholas files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →